Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
61 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pancreatic Endocrine Tumor - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pancreatic Endocrine Tumor - Pipeline Review, H2 2014', provides an overview of the Pancreatic Endocrine Tumor's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatic Endocrine Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pancreatic Endocrine Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pancreatic Endocrine Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pancreatic Endocrine Tumor pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pancreatic Endocrine Tumor Overview 6 Therapeutics Development 7 Pipeline Products for Pancreatic Endocrine Tumor - Overview 7 Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis 8 Pancreatic Endocrine Tumor - Therapeutics under Development by Companies 9 Pancreatic Endocrine Tumor - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Pancreatic Endocrine Tumor - Products under Development by Companies 13 Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development 14 Ipsen S.A. 14 Jiangsu Hengrui Medicine Co., Ltd. 15 MediaPharma s.r.l. 16 Novartis AG 17 OXiGENE, Inc. 18 Pancreatic Endocrine Tumor - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 buparlisib hydrochloride - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 dovitinib lactate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 fosbretabulin tromethamine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 lanreotide acetate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 MPHE-001B - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 SHR-1020 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 X-82 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Pancreatic Endocrine Tumor - Recent Pipeline Updates 47 Pancreatic Endocrine Tumor - Discontinued Products 57 Pancreatic Endocrine Tumor - Product Development Milestones 58 Featured News & Press Releases 58 Dec 16, 2014: Ipsen's Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 58 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 61 Disclaimer 61
List of Tables Number of Products under Development for Pancreatic Endocrine Tumor, H2 2014 7 Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Pancreatic Endocrine Tumor - Pipeline by Ipsen S.A., H2 2014 14 Pancreatic Endocrine Tumor - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 15 Pancreatic Endocrine Tumor - Pipeline by MediaPharma s.r.l., H2 2014 16 Pancreatic Endocrine Tumor - Pipeline by Novartis AG, H2 2014 17 Pancreatic Endocrine Tumor - Pipeline by OXiGENE, Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Pancreatic Endocrine Tumor Therapeutics - Recent Pipeline Updates, H2 2014 47 Pancreatic Endocrine Tumor - Discontinued Products, H2 2014 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.